CITY OF ST. JOSEPH HEALTH DEPARTMENT - COVID-19 Briefing October 4, 2021 - St. Joseph, MO
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
CITY OF ST. JOSEPH HEALTH
DEPARTMENT
COVID-19 Briefing
October 4, 2021
TESTING Locations for COVID-19 in Non-Hospital Provider Locations
Buchanan County (By Appointment Only)
**The City of St. Joseph Health Department does not have specifics on the testing process at these locations. Please visit their websites or call for more details.** Mosaic Non-Hospital Providers
For established patients
Various Locations
Call the provider directly
Pharmacy Locations Urgent Care Locations
NW Health Services
(By Appointment or Walk-in) (Walk-in Service) For established patients
1515 St Joseph Ave, St. Joseph, MO 64505
CVS Mosaic Life Care Urgent Care 2303 Village Dr, St. Joseph, MO 64506
3320 N Belt Hwy, St Joseph, MO 64506 For general public 5001 Lake Ave, St. Joseph, MO 64504
930 N Belt Hwy, St Joseph, MO 64506 1115 N Belt Hwy St. Joseph, MO 64506
(816) 271-7077
1301 S Belt Hwy, St Joseph, MO 64507 Peacock Pediatrics
https://www.cvs.com/minuteclinic/covid-19-testing For established patients
Urgent Care Express 3839 Frederick Ave. St. Joseph, MO 64506
* Not a Medicaid Provider (816) 396-6026
Hy-Vee 4776 Verona Dr, St. Joseph, MO 64506
201 N Belt Hwy, St Joseph, MO 64506 (816) 396-9500
Downing Pediatrics
https://www.hy-vee.com/my-pharmacy/services/covid-19-testing For established patients
805 N 36th St Suite B, St. Joseph, MO 64506
(816) 396-8855
Walgreens
4022 N Belt Hwy, Saint Joseph Advanced Dermatology & MediSearch
3645 Frederick Ave, Saint Joseph 64506 New and established patients; Walk-ins welcome
2620 S Belt Hwy, Saint Joseph 64503 For any corrections or 1427 Village Dr., St. Joseph, MO 64506
(816) 364-1515
https://www.walgreens.com/findcare/covid19/testing additions, please call
816.236.1491 River City Laboratory
Walk-ins, new patients, results typically within 24 hours
212 South Woodbine Road, St. Joseph, MO 64506
(816) 306-8108
VACCINATION Locations for COVID-19 Buchanan County
**The City of St. Joseph Health Department does not have specifics on the vaccination process at these locations. Please visit their websites or call for more details.**
City of St. Joseph Mosaic Life Care Pfizer Booster Dose Information
Health Department Patients that are established The FDA amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to allow for use of
with a Mosaic Provider a single booster dose (to be administered at least six months after completion of the primary series).
Health Department Clinic
(primary or specialty) can ❖ Eligible individuals include: Individuals 65 years of age and older; Individuals 18 through 64 years of age at high risk
904 S.10th St, Suite B, St. Joseph, MO 64503 of severe COVID-19; Individuals 18 through 64 years of age whose ongoing occupational exposure to COVID-19 puts
Monday – Friday, 8:00am contact the provider to
them at high risk of serious complications; Certain groups such as health care workers, teachers and day care staff,
11:00am and 1:00pm – 4:00pm schedule an appointment. grocery workers and those in homeless shelters or prisons.
1st, 2nd, 3rd Doses - Moderna & Pfizer Currently the authorization applies only to the Pfizer vaccine. You should not receive the Pfizer single booster dose if
Pfizer vaccine for ages 12 and older you were vaccinated with Moderna or J & J. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html
Pharmacies Third Dose Information for Certain
CVS – 1st, 2nd, 3rd Doses Sam's Club - 1st, 2nd, 3rd Doses Immunocompromised Persons
Moderna - 5201 N Belt Hwy (Target) , St Joseph, MO 64506 Moderna - 5201 N Belt Hwy, St Joseph, MO 64506 The FDA amended the emergency use authorizations (EUAs) for
Pfizer - 3320 N Belt Hwy, St Joseph, MO 64506 https://samsclub.com/covid Pfizer-BioNTech and the Moderna COVID-19 Vaccines to allow for the
Pfizer - 930 N Belt Hwy, St Joseph, MO 64506 use of an additional (third) dose in certain immunocompromised
Moderna - 1301 S Belt Hwy, St Joseph, MO 64507 Walgreens - 1st, 2nd, 3rd Doses
individuals. A full list of conditions can be found on CDC’s website.
https://www.cvs.com/coronavirus Pfizer - 4022 N Belt Hwy, Saint Joseph https://www.cdc.gov/coronavirus/2019-
Pfizer - 3645 Frederick Ave, Saint Joseph 64506 ncov/vaccines/recommendations/immuno.html
Hy-Vee - 1st, 2nd, 3rd Doses Pfizer - 2620 S Belt Hwy, Saint Joseph 64503
Pfizer - 201 N Belt Hwy, St Joseph, MO 64506 https://www.walgreens.com/covid
https://www.hy-vee.com/my-pharmacy/covid-vaccine
MO VIP Vaccine Program
Rogers - 1st, 2nd, 3rd Doses
Walmart - 1st, 2nd, 3rd Doses Register to win $10,000!
Moderna & Pfizer - 4201 N Belt Hwy, St Joseph MO 64506
Moderna - N Belt Hwy, St Joseph, MO 64506 The Missouri Department of Health & Senior Services is
Moderna & Pfizer - 3022 S Belt Hwy St Joseph MO 64503
(816) 232-3348—Choose option 10 to register partnering with the Missouri Lottery to draw 180 winners in
https://www.walmart.com/COVIDvaccine
5 randomized drawings (900 persons total) who will win
either $10,000 cash or $10,000 towards an education savings
account Learn More: https://covidvaccine.mo.gov/win/
www.vaccines.gov ~ 1-800-232-0233 ~ TTY 1-888-720-7489 ~Disability Info/Access Line 1-888-677-1199
MO VIP COVID-19 VACCINE INCENTIVE PROGRAM
H T T P S : / / M O S TO P S C OV I D. C O M / W I N
Next (and Final) Entry Deadline will be October 6th at 11:59pm
https://MOStopsCovid.com/win
MO VIP is our state's vaccine incentive program - rewarding those who have chosen or will choose to receive a COVID-19 vaccination.
The Missouri Department of Health & Senior Services is partnering with the Missouri Lottery to draw 180 winners in 5 randomized drawings who will win either $10,000 cash or
$10,000 towards an education savings account. In total, the state will award 900 individuals throughout the incentive program.
Vaccination is the most effective and long-lasting tool for protection from this infection. DHSS continues to encourage anyone age 12 and up to get vaccinated against COVID-19.
COVID-19 VACCINE DASHBOARD
H T T P S : / / C O V I D VA C C I N E . M O . G O V / D ATA /
Number of Number of Total COVID-19 7-Day 7-Day Avg
County people who have Percent of population people who have Percent of population Doses Doses Doses
Name Initiated vaccination initiating vaccination completed vaccination completing vaccination Administered Administered Administered
Buchanan 32,900 37.7% 30,459 34.9% 61,384 565 81
COVID-19 IN BUCHANAN COUNTY
Confirmed Probable
Total Cases Hospitalizations Deaths Positivity Rate
Cases Cases
Total Count 14,909 10,472 4,437 17 217 6.06%*
Change Since Last
+52 +40 +12 -2 +2 N/A*
Report
*Positivity rate has not been updated due to technical issues at the state. This will be updated as soon as the information has been corrected.
Confirmed case: The case meets the confirmed laboratory evidence, which is the detection of SARS-CoV-2 RNA in a clinical specimen using an approved detection test verified by a
certified testing laboratory.
Probable case: The case meets clinical criteria AND epidemiologic evidence (close contact with a confirmed or probable case; travel to or residence in an area with sustained, ongoing
community spread; or a member of a risk cohort as defined by public health authorities during an outbreak), with no confirmatory laboratory testing performed for COVID-19.
Positivity Rate - The 7-day positivity rate is based on PCR and Antigen testing rates for Buchanan County residents and will be updated once a week on Mondays.
Currently Hospitalized – Mosaic Daily Inpatient Update: COVID-19 patient count is minimal. If the Mosaic system has more than ten COVID-19 inpatients, their website will be
updated https://www.mymlc.com/General/coronavirus-covid-19/#DailyInpatientUpdate. Patients may not be Buchanan County residents.
BUCHANAN COUNTY
COVID-19 CASE DEMOGRAPHICS
Buchanan County Cases by Age Range
3000 2779 Buchanan County Cases by Gender
2453
2500
2214 2235 2160
2000
Male 7227
1575
1500 Female 7680
1000
723
570 Not Reported 2
500
0 1000 2000 3000 4000 5000 6000 7000 8000
0
Under 20 20-29 30-39 40-49 50-59 60-69 70-79 80+
BUCHANAN COUNTY
1 4 - D AY T R E N D
This is the number of new cases over the past 14 days.
The straight line shows the trend of new cases.
COVID-19
IN
MISSOURI
Missouri COVID-19 Dashboard will provide
COVID-19 data for state and county levels:
MO DHSS numbers have continued to
fluctuate as the state makes adjustments to
ensure COVID-19 cases are not counted
twice. This could occur if a person received
a positive antigen test followed up with a
confirmatory PCR test – initially some
people who fall into that category were
counted in both. In order to report
accurately, the state regularly reviews
positive tests and corrects the numbers. https://health.mo.gov/living/healthcondiseases/communicable/novel-coronavirus/data/public-health/statewide.php
COVID-19 IN THE US AND WORLDWIDE
Worldwide as of October 4, 2021 United States as of October 4, 2021
Total Cases: 234,809,103 Total Cases: 43,605,623
Total Deaths: 4,800,375 Total Deaths: 700,176
Persons Fully Vaccinated: 2,577,562,552 Persons Fully Vaccinated: 185,788,098
* Source: World Health Organization https://covid19.who.int/
Note: You likely notice a difference in the case counts if you are following other organizations, such
* Source: Center for Disease Control and Prevention https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days
as Johns Hopkins. The CDC updates case totals each day, reporting the cases numbers from the
previous day. Other sites use sources for real time counts.Three Point Shot Last week the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for a single booster shot* of the Pfizer-BioNTech COVID-19 vaccine. Certain populations are now eligible to receive a booster shot of the Pfizer-BioNTech vaccine at least 6 months after receiving their second Pfizer-BioNTech shot. These populations include people ages 65 years and older, people ages 18 years and older who have underlying medical conditions, and people ages 18 years and older who live or work in high-risk settings. The COVID-19 vaccines approved and authorized in the United States continue to be effective at reducing the risk of severe disease, hospitalization, and death. COVID-19 vaccination can also reduce the spread of disease overall and help protect the people around you. However, recent data show that protection against asymptomatic, mild, and moderate disease may decrease over time. The reduced protection may be due to both decreasing immunity over time and the highly contagious Delta variant. COVID-19 vaccination, along with layered prevention strategies, continues to be our best defense against severe disease. People who are unvaccinated remain the most vulnerable to COVID-19. To end this pandemic, it is critical that all people get vaccinated as soon as they are eligible. To find a vaccine provider near you, visit Vaccines.gov or your state or local public health department website. Talk to your healthcare provider if you have questions about whether a Pfizer-BioNTech COVID-19 booster shot is appropriate for you. *Booster shots are doses of U.S. approved or authorized vaccines that are given when protection from initial vaccination is likely to have decreased over time. Note to readers: CDC’s COVID Data Tracker recently released a COVID-19 Vaccine Effectiveness page, which allows users to view COVID-19 vaccine effectiveness at protecting against hospitalization and infection. https://covid.cdc.gov/covid-data-tracker/#vaccine-effectiveness Full report dated October 1, 2021: https://www.cdc.gov/coronavirus/2019 -ncov/covid-data/covidview/index.html
INFORMATION FOR HEALTH C ARE PROFESSIONALS
FDA NEWS RELEASE
Coronavirus (COVID-19) Update: October 1, 2021
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-october-1-2021
The U.S. Food and Drug Administration today announced the following actions taken in its ongoing
response effort to the COVID-19 pandemic:
• On Sep. 24, Janet Woodcock, M.D., Acting FDA • On Sep. 29, the FDA authorized an emergency Testing updates:
Commissioner and Peter Marks, M.D., Ph.D, use authorization (EUA) for one additional batch of • As of today, 412 tests and sample collection
director of the FDA’s Center for Biologics the Janssen COVID-19 vaccine manufactured at devices are authorized by the FDA under
Evaluation and Research, discussed the FDA’s the Emergent facility. To date, a total of nine emergency use authorizations (EUAs). These
authorization of a single booster dose of the batches of Janssen COVID-19 vaccine that were include 289 molecular tests and sample collection
Pfizer-BioNTech COVID-19 Vaccine for certain manufactured at the Emergent facility have been devices, 88 antibody and other immune response
populations with stakeholders. To listen and view authorized. The FDA conducted a thorough review tests and 35 antigen tests. There are 65 molecular
the call, visit FDA’s YouTube channel of facility records and quality testing performed by authorizations and one antibody authorization that
https://www.youtube.com/watch?v=0rx8wsEPoAk the manufacturer. Based on this review and can be used with home-collected samples. There is
considering the current COVID-19 public health one molecular prescription at-home test, three
emergency, the FDA has concluded that these antigen prescription at-home tests, seven antigen
batches are suitable for use. While the FDA is not over-the-counter (OTC) at-home tests and two
yet ready to include the Emergent BioSolutions molecular OTC at-home tests.
plant in the Janssen EUA as an authorized
• The FDA has authorized 16 antigen tests and eight
manufacturing facility, the agency continues to
molecular tests for serial screening programs. The
work through issues on this matter with Janssen
FDA has also authorized 641 revisions to EUA
and Emergent BioSolutions management.
authorizations.INFORMATION FOR HEALTH C ARE PROFESSIONALS
FDA NEWS RELEASE: October 01, 2021
FDA to Hold Advisory Committee Meetings to Discuss
Emergency Use Authorization for Booster Doses and COVID-19 Vaccines for Younger Children
https://www.fda.gov/news-events/press-announcements/fda-hold-advisory-committee-meetings-discuss-emergency-use-authorization-booster-doses-and-covid-19
Today, the U.S. Food and Drug Administration is announcing two upcoming meetings of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to discuss
newly available data for the currently available COVID-19 vaccines.
VRBPAC Meeting on Janssen and Moderna COVID-19 Vaccine Boosters VRBPAC Meeting on Pfizer Data on Its COVID-19 Vaccine for Children 5-11
On Oct. 14 and 15, the advisory committee will meet to discuss the use of booster doses of the Moderna The FDA anticipates receiving a request from Pfizer to amend its emergency use authorization to allow the use of its
COVID-19 Vaccine and the Janssen COVID-19 Vaccine. Both vaccines are currently authorized for emergency COVID-19 vaccine in children 5 through 11 years of age. In anticipation of the request, the FDA is moving
use to prevent COVID-19 in individuals 18 years of age and older. The committee will also hear presentations forward with scheduling an advisory committee meeting on Oct. 26 to inform the agency’s decision-making.
and discuss the available data on the use of a booster of a different vaccine than the one used for the primary
series of an authorized or approved COVID-19 vaccine (heterologous or “mix and match” booster). “We know from our vast experience with other pediatric vaccines that children are not small adults, and we will
conduct a comprehensive evaluation of clinical trial data submitted in support of the safety and effectiveness of the
“Vaccines are one of the most important interventions for bringing an end to the ongoing pandemic. It’s critical vaccine used in a younger pediatric population, which may need a different dosage or formulation from that used in an
that as many eligible individuals as possible get vaccinated as soon as possible. Once vaccinated, we want to
older pediatric population or adults,” said Acting FDA Commissioner Janet Woodcock, M.D.
ensure that individuals continue to be protected against the adverse effects of COVID-19. The available data
make clear that protection against symptomatic COVID-19 in certain populations begins to decrease over time,
so it’s important to evaluate the information on the use of booster doses in various populations,” said Peter
The FDA intends to make background materials for both VRBPAC meetings available to the public,
Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research.
including the meeting agendas and committee rosters, no later than two business days before each
• On Oct. 14, the committee will discuss an amendment to the emergency use authorization of the meeting: https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-
Moderna COVID-19 Vaccine for the administration of a booster dose, in individuals 18 years of age
and older.
biological-products-advisory-committee-october-14-15-2021-meeting-announcement
The FDA intends to livestream the VRBPAC meetings on YouTube Facebook, and/or Twitter. They will also
• On Oct. 15, the VRBPAC will discuss amending the emergency use authorization of Johnson and
Johnson’s Janssen COVID-19 Vaccine for the administration of a booster dose, in individuals 18 be webcast from the FDA website.
years of age and older. • Oct. 14 meeting:
o YouTube: https://youtu.be/BhlshZ7Lkr0
• Additionally, on Oct. 15, the committee will hear a presentation from the National Institute of Health’s o Yorkcast: https://fda.yorkcast.com/webcast/Play/feeef31603f54d6fb06189e7fb3074651d
National Institute of Allergy and Infectious Diseases on the heterologous use of booster doses • Oct. 14 meeting:
following the primary series of the three currently authorized or approved COVID-19 vaccines. o YouTube: https://youtu.be/c-H40GrvWz4
During the meeting, the committee will hear presentations from the companies on the data for their respective o Yorkcast: https://fda.yorkcast.com/webcast/Play/619cf18fbc6c4c598c7ee996e029bcf61d
vaccines. The FDA will also present its own analyses of each of the manufacturers’ data. There will be an open • Oct. 26 meeting:
public hearing each day during which the public will be given an opportunity to provide comments. o YouTube: https://www.youtube.com/watch?v=laaL0_xKmmAINFORMATION FOR HEALTH C ARE PROFESSIONALS
COVID-19 Science Update released: October 1, 2021, Edition 107
https://www.cdc.gov/library/covid19/10012021_covidupdate.html
Pdf of this issue: https://www.cdc.gov/library/covid19/pdf/public_pdfs/2021-10-01-Science-Update_public_final.pdf
The COVID-19 Science Update summarizes new and emerging scientific data for public health professionals to meet the challenges of this fast-moving
pandemic. Weekly, staff from the CDC COVID-19 Response and the CDC Library systematically review literature in the WHO COVID-19 database and select
publications and preprints for public health priority topics in the CDC Science Agenda for COVID-19 and CDC COVID-19 Response Health Equity Strategy.
In this update:
Vaccines:
https://www.cdc.gov/library/covid19/10012021_covidupdate.html#anchor_Vaccines
Variants:
https://www.cdc.gov/library/covid19/10012021_covidupdate.html#anchor_Variants
Health Equity:
https://www.cdc.gov/mmwr/volumes/70/wr/mm7039e2.htm?s_cid=mm7039e2_w
Natural History, Reinfection, and Health Impact
https://www.cdc.gov/library/covid19/10012021_covidupdate.html#anchor_NaturalHistory
Testing:
https://www.cdc.gov/library/covid19/10012021_covidupdate.html#anchor_Testing
In Brief:
https://www.cdc.gov/library/covid19/10012021_covidupdate.html#anchor_InBrief
Note: Adapted from Zhong et al. A) Serum spike S1 IgG antibody levels ≥14 days following 2 doses
of SARS-CoV-2 mRNA vaccine in HCWs with prior SARS-CoV-2 infection, without prior SARS-CoV-
2 infection, and in those following SARS-CoV-2 positive PCR test and before vaccination.INFORMATION FOR HEALTH C ARE PROFESSIONALS
Morbidity and Mortality Weekly Report (MMWR ) October 1, 2021 / No. 39
https://www.cdc.gov/mmwr/index2021.html
Pdf of this issue: https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7039-H.pdf
COVID-19 Related articles:
• Disparities in COVID-19 Vaccination Status, Intent, and Perceived Access for
Noninstitutionalized Adults, by Disability Status — National Immunization
Survey Adult COVID Module, United States, May 30–June 26, 2021 -
https://www.cdc.gov/mmwr/volumes/70/wr/mm7039a2.htm?s_cid=mm7039a2_w
• Association Between K–12 School Mask Policies and School-Associated
COVID-19 Outbreaks — Maricopa and Pima Counties, Arizona, July–August
2021 https://www.cdc.gov/mmwr/volumes/70/wr/mm7039e1.htm?s_cid=mm7039e1_w
• COVID-19–Related School Closures and Learning Modality Changes — United
States, August 1–September 17, 2021 -
https://www.cdc.gov/mmwr/volumes/70/wr/mm7039e2.htm?s_cid=mm7039e2_w
• Pediatric COVID-19 Cases in Counties With and Without School Mask
Requirements — United States, July 1–September 4, 2021 -
https://www.cdc.gov/mmwr/volumes/70/wr/mm7039e3.htm?s_cid=mm7039e3_w
• Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States,
August 12–September 19, 2021 -
https://www.cdc.gov/mmwr/volumes/70/wr/mm7039e4.htm?s_cid=mm7039e4_wCDCHAN-00453:
COVID-19 Vaccination for Pregnant People to Prevent
Serious Illness, Deaths, and Adverse Pregnancy Outcomes from COVID-19
September 29, 2021, 12:00 PM ET
Summary
The Centers for Disease Control and Prevention (CDC) recommends urgent action to increase Coronavirus Disease 2019 (COVID-19) vaccination
among people who are pregnant, recently pregnant (including those who are lactating), who are trying to become pregnant now, or who might
become pregnant in the future. CDC strongly recommends COVID-19 vaccination either before or during pregnancy because the benefits of
vaccination outweigh known or potential risks.
As of September 27, 2021, more than 125,000 laboratory-confirmed COVID-19 cases have been reported in pregnant people, including more than
22,000 hospitalized cases and 161 deaths.
The highest number of COVID-19-related deaths in pregnant people (n=22) in a single month of the pandemic was reported in
August 2021. Data from the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) in 2021 indicate that approximately 97%
of pregnant people hospitalized (either for illness or for labor and delivery) with confirmed SARS-CoV-2 infection were unvaccinated.
In addition to the risks of severe illness and death for pregnant and recently pregnant people, there is an increased risk for adverse pregnancy and
neonatal outcomes, including preterm birth and admission of their neonate(s) to an intensive care unit (ICU). Other adverse pregnancy outcomes,
such as stillbirth, have been reported.
Despite the known risks of COVID-19, as of September 18, 2021, 31.0% of pregnant people were fully vaccinated before or during their pregnancy.
In addition, there are racial and ethnic disparities in vaccination coverage for pregnant people. Healthcare providers should communicate the risks
of COVID-19, the benefits of vaccination, and information on the safety and effectiveness of COVID-19 vaccination in pregnancy.
Healthcare providers should strongly recommend that people who are pregnant, recently pregnant (including those who are lactating), who are
trying to become pregnant now, or who might become pregnant in the future receive one of the authorized or approved COVID-19 vaccines as soon
as possible.
Read entire CDCHAN-00453 here: https://emergency.cdc.gov/han/2021/han00453.aspINFORMATION FOR HEALTH C ARE PROFESSIONALS
COVID-19 Treatment Guidelines - September 29, 2021
The COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of
Bamlanivimab Plus Etesevimab as Post-Exposure Prophylaxis for SARS-CoV-2 Infection
Vaccination remains the most effective way to prevent SARS-CoV-2 infection. However, despite widespread availability of SARS-CoV-2 vaccines, a number of individuals are
either not fully vaccinated or cannot mount adequate responses to the vaccine. Some of these people, if infected, are at high risk of progression to serious COVID-19. On
September 16, 2021, the Food and Drug Administration (FDA) expanded the Emergency Use Authorization (EUA) indication for the anti-SARS-CoV-2 monoclonal
antibodies (mAbs) bamlanivimab plus etesevimab to allow this combination to be used as post-exposure prophylaxis (PEP) for selected individuals. Casirivimab plus
imdevimab can also be used for this indication (see the Panel’s statement on using casirivimab plus imdevimab as PEP).
Based on the EUA, the Panel recommends using bamlanivimab 700 mg plus etesevimab 1,400 mg administered as an intravenous (IV) infusion (BIII)
as PEP for people who are at high risk for progression to severe COVID-19 if infected with SARS-CoV-2 AND who have the following vaccination status AND exposure
history.
Vaccination Status:
• Not fully vaccinated (defined as people who were never vaccinated or those who received the second vaccine dose in a two-dose series or a single-dose vaccineMonoclonal Antibody (mAb) Infusion Centers
Test positive for COVID or think you may have it?
Good news, there is a treatment available that may reduce
your risk of developing serious symptoms or winding up in
the hospital.
Depending on your age, health history, and how long you’ve
had symptoms of COVID-19, you may qualify for a
promising form of treatment for the disease. It’s called
monoclonal antibody (mAb) treatment. The key is receiving
this treatment within 10 days of contracting COVID-19, so
don’t wait to see how bad your case will be!
Monoclonal antibody (mAb) treatment may also be
administered to exposed close contacts who are at high risk
for developing severe COVID-19 illness.
Talk to your doctor about a referral.
There are two locations in our region currently offering mAb therapy:
• St. Joseph - Mosaic Life Care, 5325 Faraon, St. Joseph, MO. Call your primary care provider to see
if you qualify for the infusion. Don’t have a primary care provider? Call 816-271-6503.
• Cameron - Monoclonal Antibody Infusion Center, 214 McElwain Drive, Cameron, MO. Call/text
816-312-8718 for details. You can also self-schedule to the Cameron location by visiting their
Patient Scheduling Form https://hipaa.jotform.com/212324982557057
To learn more about the monoclonal antibody infusion, visit https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patientsINFORMATION FOR HEALTH C ARE PROFESSIONALS
Missouri Department of Health and Senior Services – Health Care Professionals
https://health.mo.gov/living/healthcondiseases/communicable/novel -coronavirus/professionals.php#collapseTwo
Centers for Disease Control and Prevention (CDC) - Healthcare Workers: Information on COVID-19
https://www.cdc .gov/coronavirus/2019 -nCoV/hcp/index.html
National Institutes of Health - Coronavirus Disease 2019 (COVID-19) Treatment Guidelines
https://www.covid19treatmentguidelines.nih.gov/
U.S. Food & Drug Administration – COVID-19
https://www.fda.gov/emergency -preparedness-and-response/counter terrorism -and-emerging-threats/coronavirus -disease-2019-covid-19
U.S. Department of Health and Human Services – COVID-19
https://www.hhs.gov/coronavirus/index.html
SOURCES OF INFORMATION
Missouri Department of Health and Senior Services
https://health.mo.gov/living/healthcondiseases/communicable/novel -coronavirus/
Center for Disease Control and Prevention
h t t p s : / /w w w.c dc. g ov/ co r on avi ru s/ 20 19 - nco v/ in de x.h t m l
World Health Organization
https://covid19.who.int/You can also read
